Olomoucine II

TargetMol
Product Code: TAR-T35696
Supplier: TargetMol
CodeSizePrice
TAR-T35696-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35696-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35696-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Olomoucine II is an inhibitor of cyclin-dependent kinases (CDKs; IC50s = 7.6, 0.1, 19.8, 0.45, and 0.06 μM for Cdk1, -2, -4, -7, and -9, respectively).1It is selective for CDKs over 10 additional kinases (IC50s = >100 μM for all) but does inhibit ERK2 (IC50= 32 μM) and the ATP-binding cassette transporter B1 (ABCB1; IC50= 6.4 μM).1,2Olomoucine II inhibits proliferation of a variety of cancer cells, including those expressing wild-type p53 or mutant p53 (mean IC50s = 7.4 and 10.1 μM, respectively), and it acts synergistically with daunorubicin to inhibit proliferation of HCT-8 cells that endogenously express ABCB1. Olomoucine also inhibits replication of herpes simplex virus 1 (HSV-1), HSV-2, vaccinia virus, human adenovirus type 4 (Ad4), and human CMV (IC50s = 5, 4.7, 3.8, 2.4, and 3.2 μM, respectively) but not measles virus or influenza virus (IC50s = >20 μM for both).3
CAS:
500735-47-7
Formula:
C19H26N6O2
Molecular Weight:
370.5
Purity:
0.98
SMILES:
OC[C@H](NC1=NC(NCC2=C(O)C=CC=C2)=C3N=CN(C(C)C)C3=N1)CC

References

Cihalova, D., Hofman, J., Ceckova, M., et al.Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitroPLoS One8(12)e83467(2013) Holcakova, J., Tomasec, P., Bugert, J.J., et al.The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral propertiesAntivir. Chem. Chemother.20(3)133-142(2010) Kry?tof, V., McNae, I.W., Walkinshaw, M.D., et al.Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitorCell Mol. Life Sci.62(15)1763-1771(2005)